Author

Deanna H. Wong

Barnes-Jewish HospitalORCID 0000-0003-4622-0511Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Amanda J. CompadreiD· 1 shared Danielle Kemper· 1 shared Dineo KhabeleiD· 1 shared Elena LomonosovaiD· 1 shared Elizabeth L. ChristieiD· 1 shared Kathleen E. Jackson· 1 shared Kellen Zoberi· 1 shared Lindsey N AubuchoniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Amanda J. CompadreORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintMar 4, 2026

Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancers

Lindsey N Aubuchon, Deanna H. Wong, Natasha Ramakrishnan…·Priyanka Verma

This study shows that targeting ALC1 can enhance PARP inhibitor effectiveness in ovarian cancers, particularly in HRD and CCNE1-amplified tumors, with minimal toxicity.

DOI 10.64898/2025.12.04.692458

humanbulk RNA-seq

𝕏 PostBluesky